»õ·Î¿î ´Ù¾àÁ¦³»¼º ±Øº¹Á¦ KR-30035°¡ ¾Ï¼¼Æ÷ÀÇ Tc-99m MIBI¼·Ãë¿¡ ¹ÌÄ¡´Â ¿µÇâ
Effects of a New Multidrug-Resistance Reversing Agent, KR-30035, on Tumoral Uptake of Tc-99m MIBI In-vitro and In-vivo
¼Ò¼Ó »ó¼¼Á¤º¸
Á¶ÀÎÈ£
ÀÌÀçÅÂ/¼Àå¼ö/À̺´È£/ÃÖ»ó¿î/¼Õ»ó±Õ/ÀÌÁ¤¿Á/À¯¼ºÀº/Á¤Áرâ
KMID : 0360319990310040773
Abstract
¼·Ð
¾Ç¼ºÁ¾¾çÀÇ Ç×¾ÏÁ¦ Ä¡·á¿¡ ÀÖ¾î Ä¡·á½ÇÆÐ¿Í Àç¹ßÀÇ ÁÖµÈ ¿øÀÎÀÎ ¾àÁ¦³»¼ºÀÇ °¡Àå Áß¿äÇÑ
¿øÀÎÀº ´Ù¾àÁ¦³»¼º À¯ÀüÀÚ(multidrug resistance gene; mdr1 gene)ÀÇ ¹ßÇö¿¡ ÀÇÇÑ 170 kDa
ÀÇ ¼¼Æ÷¸· ´Ü¹éÁúÀÎ P-´ç´Ü¹é (P-glycoprotein, p-gp)ÀÇ °ú´Ù¹ßÇö¿¡ ÀÖ´Ù. ATP-binding
cassette transporter±ºÁßÀÇ ÇϳªÀÎ P-´ç´Ü¹éÀº ¿¡³ÊÁö ÀÇÁ¸¼º ¹èÃâÆßÇÁ·Î¼ ºóÄ«¾ËÄ®·ÎÀÌ
µå, anthracyclings°è Ç×¾ÏÁ¦, epipodophyllotoxins, paclitaxel°ú °°Àº ÇÕ¼º ÈÇпä¹ý¾ÇÁ¦µéÀ»
¼¼Æ÷ ¹ÛÀ¸·Î ¹èÃâ½ÃÄÑ ´Ù¾àÁ¦ ³»¼ºÀ» À¯¹ßÇÑ´Ù. ¾Ç¼ºÁ¾¾ç¿¡¼ ÈÇпä¹ýÀÌ ½ÇÆÐÇÑ °æ¿ìÀÇ »ó
´ç¼ö¿¡¼´Â mdr1 mRNAÀÇ ¹ßÇö°ú ¾Ï¼¼Æ÷ÀÇ P-´ç´Ü¹éÀÌ Áõ°¡µÇ¾î ÀÖÀ½ÀÌ ¸¹Àº ȯÀÚµéÀÇ
¾Ï¼¼Æ÷³ª Á¶Á÷ÀýÆí¿¡¼ Áõ¸íµÈ ¹Ù ÀÖ´Ù. ÇöÀç±îÁöµµ ¾Ç¼ºÁ¾¾çÀÇ Ç×¾ÏÈÇпä¹ý½Ã ´Ù¾àÁ¦ ³»
¼ºÀ» ±Øº¹ÇÏ´Â °ÍÀº Ç×¾ÏÄ¡·áÀÇ ¼ºÆи¦ °áÁ¤ÇÏ´Â Áß¿äÇÑ ÀÎÀÚÀÌ´Ù.
P-´ç´Ü¹é¿¡ ÀÛ¿ëÇÏ¿© ´Ù¾àÁ¦ ³»¼ºÀ» ¿ªÀü½Ãų ¼ö ÀÖ´Â ¾àÁ¦µé·Î´Â Ä®½· Åë·Î Â÷´ÜÁ¦,
quinine À¯»çü, calmodulin ±æÇ×Á¦, isoprenoids, tamoxifen, reserpine À¯»çü,
acridonecarboxamides, cyclosporin, triazinoaminopiperidines, FKBP °áÇÕ¸®°£µå¿Í °°Àº Á¦
ÀçµéÀÌ ÀÖ´Ù. À̵éÀº ´Ù¾àÁ¦ ³»¼ºÀÎÀÚ¿Í °ü·ÃµÈ À¯Ãâ ¼ö¼ÛÀÎÀÚÀÎ P-´ç´Ü¹éÀÇ °øÅë°áÇÕºÎÀ§
¿Í °æÀïÇϰųª, ´Ü¹éÁú³»ÀÇ ÀÎÁö ºÎÀ§¿ÍÀÇ Ä£È¼ºÀ» º¯È½ÃÄÑ ¾Ç¼ºÁ¾¾ç ¼¼Æ÷³× ¼¼Æ÷µ¶¼ºÁ¦
ÀÇ ³óµµÁõ°¡·Î ´Ù¾àÁ¦ ³»¼ºÀÎÀÚÀÇ ¿ªÇÒÀ» ¹«·ÂÈÇÑ´Ù. Ä®½· Åë·Î »ç´ÜÁ¦ÀÎ verapamilÀº P-
´ç´Ü¹éÀ¸·Î Ç¥ÇöµÇ´Â ´Ù¾àÁ¦ ³»¼ºÀÎÀÚÀÇ Á¶Àý¹°ÁúÁß Çϳª·Î¼, ½ÇÁ¦ ÀÓ»ó¿¡¼ °¡Àå ¸ÕÀú »ç
¿ëµÈ ¹Ù°¡ ÀÖ´Ù. ±×·¯³ª, verapamilÀº ´Ù¾àÁ¦ ³»¼ºÀÎÀÚ¸¦ ¿ªÀü½Ãų ¼ö ÀÖ´Â Ç÷Á߳󵵿¡¼ Àú
Ç÷¾Ð, ¿ïÇ÷¼º ½ÉºÎÀü, ÀüµµÀå¾Ö¿Í °°Àº ½ÉÀ嵶¼ºÀ» ÃÊ·¡Çϱ⠶§¹®¿¡ ´Ù¾àÁ¦ ³»¼ºÀ» ±Øº¹ÇÒ
¼ö ÀÖ´Â °í¿ë·®À» ½ÇÁ¦ ÀÓ»ó¿¡¼ »ç¿ëÇϱâ´Â ¾î·Æ´Ù. Cyclosporin Aµµ ´Ù¾àÁ¦ ³»¼ºÀÎÀÚ¸¦
¿ªÀü½Ãų ¼ö ÀÖÀ¸³ª °í¿ë·®ÀÌ ÇÊ¿äÇϸç, ÀÌ ¶§ ½ÉÇÑ ½Åµ¶¼ºÀÌ ¹®Á¦°¡ µÈ´Ù°í Àӻ󿬱¸¿¡¼
º¸°íµÇ¾ú´Ù. µû¶ó¼, ¹Ù¶÷Á÷ÇÏÁö ¾ÊÀº ÀÎüÀÇ µ¶¼ºÈ¿°ú´Â Àû°í ´Ù¾àÁ¦ ³»¼ºÀÇ ¿ªÀüÈ¿°ú´Â Å«
Á¦ÀçµéÀÌ ¿¬±¸µÇ°í ÀÖ´Ù. ÃÖµîÀº »õ·Î¿î Ä®½· Åë·Î Â÷´ÜÁ¦ÀÎ KR-30035¸¦ ÇÕ¼ºÇÏ°í,
KR-30035°¡ ½ÉÇ÷°ü ¾à¸®ÀÛ¿ëÀº verapamilº¸´Ù ÀûÀ¸¸é ¼, P-´ç´Ü¹éÀÌ ¹ßÇöµÈ ÀÎü ¾Ï¼¼Æ÷
ÁÖ¿¡¼ÀÇ ·Î´Ù¹Î ¹èÃâ´ÉÀ¸·Î ÃøÁ¤ÇÑ ´Ù¾àÁ¦ ³»¼ºÀÎÀÚÀÇ ¿ªÀüÈ¿°ú´Â ´õ Å« °ÍÀ¸·Î º¸°íÇÏ¿´
´Ù.
´Ù¾àÁ¦ ³»¼ºÀÎÀÚ´Â ¼¼Æ÷¸·¿¡¼ »ý¼ºÀÌ µÇ¹Ç·Î, »ý°ËÀ̳ª ¼ö¼ú¿¡¼ ¾òÀº ¾ÏÁ¶Á÷ÀÇ ¸é¿ªÈ
ÇÐÀû ¿°»ö¹ý, ºÐÀÚ»ý¹°ÇÐÀû ºÐ¼®¹ýÀ̳ª »ýÁ¸µÈ ¼¼Æ÷³» ·Î´Ù¹Î¹èÃâ´É µîÀ» ÃøÁ¤ÇÔÀ¸·Î¼ ü
¿Ü(in-vitro)¿¡¼ Áõ¸íÀ» ÇÒ ¼ö ÀÖ´Ù. ÇÙÀÇÇÐ ºÐ¾ß¿¡¼ ½ÉÀå°ü·ùÀÇ Æò°¡¿¡ ³Î¸® »ç¿ëÁßÀÎ
Tc-99m MIBI (methoxyisobutylisonitrile)´Â ÈÇÐÀûÀ¸·Î Tc (I)ÀÇ Á߽ɿ¡ 6°³ÀÇ MIBI°¡ µÑ
·¯½Ñ ¸ð¾çÀ» ÇÏ°í ÀÖ´Â ¾ÈÁ¤µÈ ´Ü°¡ÀÇ Áö¿ë¼º ¾çÀÌ¿ÂÈÇÕ¹°·Î¼ ü³»¿¡¼ À¯ÀÇÇÑ ´ë»ç°¡ ÀÏ
¾î³ªÁö ¾Ê°í ÀÌ¿ÂȽÃų ¼ö ÀÖ´Â ÈÇб⸦ °¡Áö°í ÀÖ´Ù. Piwnica-WormsµîÀº ´Ù¾àÁ¦ ³»¼º
À» À¯µµÇÑ ÀÎü¾Ï¼¼Æ÷¿¡¼ ¼¼Æ÷¸·ÀÇ P-´ç´Ü¹éÀÌ Tc-99m MIBI¸¦ ¼¼Æ÷¹Ù±ùÀ¸·Î ¹èÃâ½ÃÅ´À¸
·Î¼ ¼¼Æ÷³» Àú·ù°¡ °¨¼ÒµÇ±â ¶§¹®¿¡ Tc-99m MIBI·Î ¾òÀº ¿µ»óÀ¸·Î ¾Ç¼ºÁ¾¾çÀÇ ´Ù¾àÁ¦
³»¼ºÀÎÀÚÀÇ ¹ßÇöÁ¤µµ¸¦ ¿¹ÃøÇÒ ¼ö ÀÖ´Ù°í ÇÏ¿´´Ù.
º» ¿¬±¸´Â ºÐÀÚ»ý¹°ÇÐÀû¹æ¹ýÀ¸·Î ´Ù¾àÁ¦ ³»¼ºÀÎÀÚÀÇ Á¶Á÷³» Á¸À縦 Áõ¸íÇϴ ü¿Ü¿µ»ó¹ý
ÀÇ ±âÃʸ¦ È®¸³ÇÏ°í, »õ·ÎÀÌ ÇÕ¼ºµÈ KR-30035ÀÇ ´Ù¾àÁ¦ ³»¼º¿¡ ´ëÇÑ ¿ªÀüÈ¿°ú¸¦ Æò°¡Çϱâ
À§ÇÏ¿© ´Ù¾àÁ¦ ³»¼ºÀÌ À¯µµµÈ ¾Ç¼ºÁ¾¾ç¼¼Æ÷¿Í ÀÎüÁ¾¾çÀÌ½Ä ´©µå¸¶¿ì½º¿¡¼ verapamil°ú
H3-30035ÀÇ Á¾¾ç³» Tc99m MIBI ¼·Ãë¿¡ ¹ÌÄ¡´Â È¿°ú¸¦ ºñ±³ Æò°¡ÇÏ¿´´Ù.
Purpose : Verapamil is one of the most extensively characterized modulators of
P-glycoprotein (P-gp) mediated multi-drug resistance (MDR), but its plasma
concentration required to reverse MDR can cause cardiovascular toxicity. KR-30035 is a
newly synthesized verapamil analogue with more potent cytostatic effects, but has lower
cardiovascular effects than verapamil. We have assessed the MDR reversing effects of
KR-30035 by measuring Tc-99m MIBI uptake in cultured tumor cells and in nude mice
bearing human tumor xenografts.
Materials and Methods : In-vitro uptake of Tc-99m MIBI was measured in murine
leukemia cells (L-1210) and those MDR-positive variants after incubation with different
concentrations of KR-30035. Results were compared to those with verapamil. Organ and
tumoral uptake of Tc-99m MIBI was compared between P-gp (+) human colon cancer
(HCT15 cells) and P-gp (-) lung cancer (A549 cells) in nude mice, treated with either
KR-30035 or verapamil.
Results : There was no significant difference in in-vitro uptake of Tc-99m MIBI
between verapamil and KR-30035 group at any concentrations. MIBI uptake in P-gp (+)
cells continuously increased either with verapamil or KR-30035 in a dose-dependent
manner Tc-99m MIBI uptake ratios of the tumor [P-gp (+) tumor uptake divided by
P-gp (-) uptake] were significantly higher with KR-30035 than with verapamil in tumor
bearing nude mice. Washout rate of Tc-99m MIBI from P-gp (+) HCT15 cells was
lower in verapamil or KR-30035 groups than in the control group, which was 0.19, 0.19
and 0.27 respectively.
Conclusion : These studies revealed that KR-30035 can potentially be used as an
active modulator of MDR, with its significantly lesser cardiovascular toxicity than
verapamil. Our results warrants further evaluation of this novel agent.
Å°¿öµå
KR-30035; Verapamil; Multi-drug resistance; Tc-99m MIBI;
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸